Repare Therapeutics has entered into a definitive agreement to be acquired by XenoTherapeutics, offering shareholders approximately $1.82 per share and potential future royalties.

Target Information

Repare Therapeutics Inc. is a clinical-stage precision oncology company based in Cambridge, Massachusetts and Montreal, with a particular focus on developing novel therapeutics through its proprietary synthetic lethality approach. The company specializes in highly targeted cancer therapies that address genomic instability and DNA damage repair. Repare's current clinical pipeline includes two promising candidates: RP-3467, a Polθ ATPase inhibitor, and RP-1664, a PLK4 inhibitor.

As of September 30, 2025, Repare reported $112.6 million in cash, cash equivalents, and marketable securities, reflecting a steady financial position compared to $109.5 million at the end of June 2025. Following its definitive agreement to be acquired by XenoTherapeutics, Inc., the company anticipates transitioning to a private entity and ceasing to be a reporting issuer under Canadian and U.S. securities regulations.

Industry Overview

The precision oncology industry is rapidly evolving, driven by advancements in genomic research and targeted therapies aimed at increasing treatment efficacy for cancer patients. Particularly in No